JC
ACRS icon

Jetstream Capital’s Aclaris Therapeutics ACRS Stock Holding History

Jetstream Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-140,000
Closed -$2.52M – 24
2021
Q3 		$2.52M Buy
+140,000
New +$2.24M 2.44% 17

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jetstream Capital's ACRS Position: Q4 2021 in Review

Jetstream Capital sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 140,000 shares — an estimated $2.52M sold.

Jetstream Capital first reported a position in ACRS in Q3 2021 and held it in 1 quarter. The position peaked at $2.52M in Q3 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • Jetstream Capital reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jetstream Capital sold 140,000 Aclaris Therapeutics shares in Q4 2021, an estimated $2.52M.
  • Jetstream Capital first reported a position in Aclaris Therapeutics in Q3 2021 and held it in 1 quarter.
  • Jetstream Capital's Aclaris Therapeutics position peaked at $2.52M in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on Jetstream Capital's 13F filing for Q4 2021, filed 14 Feb 2022.